STOER For Men with CBD oil

Labskin CBD tests show greater than 99% reduction in bacterial growth on human skinIntegumen plc (AIM: SKIN) is pleased to announce a greater than 99% reduction of bacterial growth in preliminary results of four formulations, all of which include Cannabinoid (CBD)...

TSpro disposal removes £1.19m liabilities

Divestment of TSPro GmbH to remove c€1.34m (£1.19m) of short and long term liabilities from Integumen Today the Company announces the divestment (“Disposal”) of TSpro GmbH (“TSPro”), a wholly-owned subsidiary of Integumen plc. The Company has entered into a...

Labskin On A Chip

Labskin-On-A-Chip to monitor real-time skin related diseases and Labskin-AI data analysis to predict the best course of treatmentIntegumen is pleased to announce a cross-platform biophysics agreement with AI developer, Rinocloud Limited, in association with Cork...

Artificially Intelligent Labskin

First laboratory-grown human-skin test service, to use artificial intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care products. Labskin (Innovenn Ltd.), a wholly-owned subsidiary of Integumen plc., (AIM:SKIN) today announces that...

Trading Update August 2018

Chairman's Statement Introduction Since Integumen’s  admission to trading on AIM in April 2017, the integration of multiple isolated and diverse business units covering oral-care, cosmetics, wound care and supported by an animal-free laboratory grown human skin...

Interim Results 2018

  Interim Report 2018 Integumen (LSE: SKIN), the non-animal-testing, skin care and cosmetic businesses developing and commercialising technologies and products for consumer use today announces its interim results for the 6 months ended 30 June 2018. Performance...

Share This